BPC-157 vs Cortisone Shots: Which Approach Has More Evidence?

What Cortisone Shots Actually Do

Cortisone is a corticosteroid — a powerful anti-inflammatory hormone. When injected into a joint or tendon sheath, it rapidly reduces inflammation and pain. That’s the good news.

The bad news is what cortisone does to the tissue underneath the inflammation:

• It inhibits collagen synthesis — the process that repairs tendon and cartilage
• It causes dose-dependent cell death in tendon cells (tenocytes)
• Repeated injections accelerate cartilage degradation in joints
• It weakens tendons — increasing rupture risk in the weeks after injection

This is the cortisone paradox: it reduces inflammation (the symptom) while potentially worsening the underlying tissue damage (the cause). Multiple systematic reviews confirm that repeat cortisone injections lead to worse long-term outcomes than physical therapy alone for conditions like plantar fasciitis, Achilles tendinopathy, and knee osteoarthritis.

What BPC-157 Does in Research

BPC-157 (Body Protection Compound 157) works through the opposite mechanism. Instead of suppressing the inflammatory response, it works downstream — accelerating the actual tissue repair process.

In tendon, ligament, and joint research, BPC-157 has consistently shown:

• Increased collagen synthesis (the opposite of cortisone)
• Faster fibroblast migration into repair zones
• Improved tendon-to-bone healing in animal models
• New blood vessel formation (angiogenesis) into damaged tissue
• Reduced inflammatory cytokines without inhibiting repair

The key distinction: BPC-157 appears to reduce inflammation while also stimulating repair. Cortisone reduces inflammation while suppressing repair.

View BPC-157 →

Evidence Comparison: Quantity vs Quality

Cortisone Evidence

Cortisone injections have decades of clinical evidence — including large randomized controlled trials and systematic reviews in humans. The short-term pain relief is well-established. The long-term harm is also well-established. It’s not lack of evidence that’s the problem with cortisone — it’s that the evidence increasingly shows poor long-term outcomes with repeated use.

BPC-157 Evidence

BPC-157 has a growing body of animal model research — primarily in rats and rabbits. The results are consistently positive for tendon, ligament, bone, and gut healing. Human clinical trials are essentially nonexistent in published literature as of this writing.

This is the critical gap: BPC-157 has compelling animal data but lacks the human trial validation that cortisone (for better or worse) has accumulated.

Head-to-Head Comparison

The Research Argument for BPC-157

The argument for studying BPC-157 as a cortisone alternative isn’t that it definitely works better in humans — we don’t know that yet. The argument is that:

1. Cortisone’s long-term harms are increasingly well-documented
2. BPC-157’s mechanism (pro-repair rather than anti-repair) is theoretically superior
3. Animal data is consistently positive without the tissue-damage side effects seen with cortisone
4. The gap in treatment options for tendinopathy and joint degeneration justifies investigation

What’s Needed

Human clinical trials. That’s the honest answer. BPC-157’s animal data is compelling, but it needs to be tested in controlled human studies before any meaningful comparison to cortisone is possible. Several research groups are in early-phase investigation; results are years away.

Summary of Key Research References

Written by the NorthPeptide Research Team